Inhibition of Oral Mucosal Cell Wound Healing by Bisphosphonates

Overview

Journal J Oral Maxillofac Surg

Specialties Dentistry
General Surgery

Date 2008 Apr 22

PMID 18423269

Citations 82

Authors

Regina Landesberg

Matthew Cozin

Serge Cremers

Victoria Woo

Stavroula Kousteni

Satrajit Sinha

LeeAnn Garrett-Sinha

Srikala Raghavan

Affiliations

Soon will be listed here.

Abstract

Purpose: Bisphosphonates (BPs) are a widely used class of drugs that are effective in the treatment and prevention of osteoporosis, hypercalcemia of malignancy, and bone metastases associated with multiple myeloma, breast cancer, and other solid tumors. In the past several years there have been numerous reports describing the occurrence of osteonecrosis of the jaws (ONJ) associated with these drugs. Whether the ONJ lesion initiates in the oral mucosa or derives from the underlying bone is not well understood. In this report we describe the effect of pamidronate, a second-generation BP, on oral mucosal cells.

Materials And Methods: Murine oral keratinocytes were isolated and exposed to pamidronate at a range of clinically relevant doses. Cellular proliferation was measured using a MTS/PMS reagent-based kit and wound healing was examined with a scratch assay. To determine whether oral keratinocytes undergo apoptosis following exposure to pamidronate, TUNEL, caspase-3, and DAPI apoptosis assays were performed.

Results: We show that BP pretreatment of oral mucosal cells inhibits proliferation and wound healing at clinically relevant doses, and that this inhibition is not due to cellular apoptosis.

Conclusions: To our knowledge this is the first report investigating the effect of nitrogen-containing BPs on oral mucosal cells. This study suggests that BPs inhibit oral keratinocyte wound healing which may play a significant role in the initiation of ONJ.

Citing Articles

Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System.

Wang L, Zhang W, Zhao C, Fu Z Front Endocrinol (Lausanne). 2024; 15:1367607.

PMID: 39239094 PMC: 11374645. DOI: 10.3389/fendo.2024.1367607.

The effect of antiresorptive therapy on the prevalence and severity of oral lichen planus: a retrospective study.

Parvini P, Obreja K, Cafferata E, Aini T, Lermen Y, Begic A BMC Oral Health. 2024; 24(1):547.

PMID: 38730315 PMC: 11088150. DOI: 10.1186/s12903-024-04331-5.

Interactive Associations between and and Bisphosphonate-Related Osteonecrosis of the Jaw in Patients with Osteoporosis.

Kim J, Kim J, Yee J, Kim S, Chung J, Gwak H Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513946 PMC: 10386002. DOI: 10.3390/ph16071035.

Intermittent parathyroid hormone enhances the healing of medication-related osteonecrosis of the jaw lesions in rice rats.

Castillo E, Jiron J, Croft C, Freehill D, Castillo C, Kura J Front Med (Lausanne). 2023; 10:1179350.

PMID: 37404809 PMC: 10315582. DOI: 10.3389/fmed.2023.1179350.

A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.

Sobczak-Jaskow H, Kochanska B, Drogoszewska B Medicina (Kaunas). 2023; 59(6).

PMID: 37374277 PMC: 10301423. DOI: 10.3390/medicina59061073.

References

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

Anthony Pogrel M . Bisphosphonates and bone necrosis. J Oral Maxillofac Surg. 2004; 62(3):391-2. DOI: 10.1016/j.joms.2003.11.003. View

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank M, Phipps R . Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001; 29(4):336-43. DOI: 10.1016/s8756-3282(01)00589-0. View

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M . Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002; 8(5):1080-4. View

Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Mackey J . Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7(5):377-87. View

Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart J . Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302(3):1055-61. DOI: 10.1124/jpet.102.035295. View

Hoggarth C, Bennett R, Daley-Yates P . The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int. 1991; 49(6):416-20. DOI: 10.1007/BF02555853. View

10.

de Groen P, Lubbe D, Hirsch L, Daifotis A, STEPHENSON W, Freedholm D . Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335(14):1016-21. DOI: 10.1056/NEJM199610033351403. View

11.

Twiss I, de Water R, den Hartigh J, Sparidans R, Brill H, Wijdeveld M . Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci. 1994; 83(5):699-703. DOI: 10.1002/jps.2600830521. View

12.

Cremers S, Papapoulos S, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P . Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res. 2005; 20(9):1543-7. DOI: 10.1359/JBMR.050522. View

13.

Hamma-Kourbali Y, Di Benedetto M, Ledoux D, Oudar O, Leroux Y, Lecouvey M . A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun. 2003; 310(3):816-23. DOI: 10.1016/j.bbrc.2003.09.083. View

14.

Loro L, Vintermyr O, Johannessen A . Apoptosis in normal and diseased oral tissues. Oral Dis. 2005; 11(5):274-87. DOI: 10.1111/j.1601-0825.2005.01117.x. View

15.

Evan G, Vousden K . Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411(6835):342-8. DOI: 10.1038/35077213. View

16.

Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C . Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem. 2003; 278(44):43603-14. DOI: 10.1074/jbc.M308114200. View

17.

Huerta S, Goulet E, Huerta-Yepez S, Livingston E . Screening and detection of apoptosis. J Surg Res. 2007; 139(1):143-56. DOI: 10.1016/j.jss.2006.07.034. View

18.

Ruggiero S, Gralow J, Marx R, Hoff A, Schubert M, Huryn J . Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2010; 2(1):7-14. PMC: 2794643. DOI: 10.1200/JOP.2006.2.1.7. View

19.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

20.

Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O . Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med. 2004; 117(6):440-1. DOI: 10.1016/j.amjmed.2004.04.015. View